Microdermics’ hollow microneedle platform provides a reliable, painless, and cost-effective means of delivering therapeutics and vaccines. Whereas traditional hypodermic needles inject into the blood, the microneedles inject into the skin, eliminating the pain and bleeding usually associated with receiving an injection. The company also designs, tests, and produces customized microneedles for the delivery of vaccines and therapeutics that will eliminate the reliance on traditional hypodermic needles.
The e@UBC Seed Fund has invested in Microdermics in December 2016. Read more about it here.